Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG2737 in adults with rapidly progressive autosomal dominant polycystic kidney disease
NL-OMON55300Phase 2Active, not recruiting
- Sponsor
- Galapagos NV
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GLPG2737 in autosomal dominant polycystic kidney disease (ADPKD) (3 arms), sponsored by Galapagos NV. Primary endpoints: Mean percent change from baseline of height-adjusted total kidney volume and Safety and tolerability. Started Nov 2020; status: active, not recruiting.
02
Drugs
GLPG2737
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NL-OMON55300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55300.